Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
2(50.0%)
Phase 3
1(25.0%)
Phase 2
1(25.0%)
4Total
N/A(2)
Phase 3(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT01099176Not ApplicableCompleted

Effects of Hypolipemic Treatment on Adipokines

Role: collaborator

NCT00620217Phase 2Completed

Angiogenesis Using VEGF-A165/bFGF Plasmid Delivered Percutaneously in No-option CAD Patients; a Controlled Trial

Role: collaborator

NCT00819442Not ApplicableUnknown

Relationship Between Abnormalities of Desmin Cytoskeleton, Mitochondrial Activity and Expression of Ubiquitin in Aspect of Pathogenesis of Heart Failure and Prognosis

Role: lead

NCT00559351Phase 3Terminated

RCT on the Combined Modality Treatment of Squamous Cell Carcinoma of the Esophagus

Role: lead

All 4 trials loaded